TCRT News & Events

Alaunos Therapeutics reported an integrated preclinical readout for ALN1003, the company's investigational oral, non-hormonal, non-incretin small-molecule candidate for obesity and related metabolic disorders. The readout consolidates findings from two non-Good Laboratory Practice diet-induced obesity mouse studies previously reported on March 2, 2026 and May 18, 2026, together with newly assembled cross-study analyses presented in an accompanying non-confidential slide deck published today. Viewed together, the data show treatment-associated improvements across key biological drivers of metabolic disease: Body weight and food intake; Body composition - preferential reductions in fat mass with proportional gains in lean mass as a percentage of body weight; Insulin-resistance biology - lower fasting insulin and lower HOMA-IR, after adjustment for adiposity; Adipose endocrine signaling - significantly higher adiponectin and a higher adiponectin-to-leptin ratio; Hepatic biology - lower liver weight, lower liver-injury and cholestatic enzymes, and qualitative liver histology findings consistent with lower hepatic steatosis. The longer-duration 48-day study evaluated ALN1003 administered orally, twice daily, at a single dose level. It is in this study that the fullest expression of the multi-axis profile was observed - the coordinated metabolic profile referenced above - with treatment-associated changes spanning body weight, insulin-resistance biology, adipose endocrine signaling, and hepatic biology. The shorter 18-day dose-ranging study evaluated ALN1003 administered in drinking water at low, medium, and high dose levels. DIO Study 2 demonstrated dose-associated changes in body weight, body composition, liver weight, glucose, and total cholesterol. Interpretation of DIO Study 2 should consider dose-related reductions in water consumption and apparent dose aversion, which may confound attribution of effects solely to drug exposure in this administration paradigm; the company is pursuing formulation optimization and dedicated PK/tolerability work.

Alaunos Therapeutics announced updated preclinical data from non-GLP diet-induced obesity mouse studies evaluating ALN1003, the company's investigational oral metabolic therapeutic candidate. Across selected biomarker and liver histology assessments, ALN1003 showed effects on insulin-resistance-related measures, adipose endocrine markers, and qualitative liver pathology findings relevant to metabolic syndrome biology. These findings support continued preclinical development of ALN1003 in metabolic syndrome and related conditions, including obesity, metabolic dysfunction-associated steatotic liver disease and insulin resistance. Metabolic syndrome is increasingly understood not as a collection of independent risk factors, but as a multi-organ, adiposity-associated disease state characterized by insulin resistance, dysfunctional adipose tissue, chronic low-grade inflammation, and hepatic lipid accumulation. Emerging research suggests that the biological quality and endocrine function of adipose tissue, rather than fat mass alone, plays a central role in disease progression. Within this framework, the preclinical profile of ALN1003 is notable in that it appears to engage several of these interconnected systems simultaneously. In the longer-duration 48-day DIO model, ALN1003 was associated with significantly lower fasting insulin and significantly lower Homeostasis Model Assessment of Insulin Resistance, a calculated index derived from fasting glucose and insulin. ALN1003-treated animals had significantly lower HOMA-IR scores compared with controls after adjustment for percentage body fat in a standard ANCOVA analysis, with the same conclusion confirmed using heteroscedasticity-robust HC3 standard errors as a sensitivity analysis. ALN1003 was also associated with numerically lower leptin, significantly higher adiponectin, and a significantly higher adiponectin-to-leptin ratio. Together, these findings are consistent with improved insulin-resistance-related biomarkers and favorable adipose endocrine signaling in this preclinical model. Liver histology findings provided additional supportive evidence relevant to the liver component of metabolic syndrome. In a blinded pathology review of selected liver samples from the 48-day and 18-day DIO studies, H&E-stained whole-slide images were evaluated for steatosis, lobular inflammation, ballooning degeneration, and NAS components, while Masson's trichrome-stained sections were used to assess fibrosis. ALN1003-treated animals showed qualitative findings consistent with lower hepatic steatosis relative to controls, along with lower mean NAS scores. Control samples evaluated in the selected pathology set had NAS scores of 5, consistent with more active steatotic liver disease-like histology, while ALN1003-treated samples had lower mean NAS scores of 2.7 and 1.3 in the 48-day and 18-day studies, respectively. These limited pilot pathology findings do not establish MASLD resolution, fibrosis reversal, inflammation improvement, or clinical efficacy, but are consistent with a qualitative anti-steatotic effect in this preclinical model. Taken together, these findings suggest that ALN1003 may influence multiple components of metabolic syndrome biology in DIO mouse models, including insulin-resistance-related biomarkers, adipose endocrine signaling, and hepatic lipid accumulation. This multi-axis preclinical profile may be relevant to a therapeutic landscape increasingly focused on metabolic health beyond body weight alone, including liver health, cardiometabolic risk, and preservation of lean mass. The Company plans to continue advancing ALN1003 through additional preclinical studies focused on dose optimization, exposure-response relationships, expanded metabolic phenotyping, and further characterization of liver pathology and underlying mechanisms. These findings are based on non-GLP preclinical studies and should be interpreted with appropriate caution. Limitations include limited sample sizes, histological analysis limited to a sample of available livers, single-timepoint biomarker assessments, known constraints of HOMA-IR interpretation in rodent models, and qualitative/semi-quantitative pathology scoring. ALN1003 has not been evaluated in human clinical trials, and its safety and efficacy in humans has not been established. As of March 31, the company had cash and cash equivalents of approximately $0.354M. The company's current cash runway extends into the second quarter of 2026. The company intends to pursue additional financing to support continued operations and advancement of its preclinical obesity and metabolic disorders program.

Valion Bio (VBIO) announced the appointment of Melinda Lackey as General Counsel and Senior Vice President of Legal Affairs. Lackey brings nearly two decades of combined scientific and legal experience across clinical-stage biopharmaceutical development, intellectual property strategy, and Nasdaq public company governance, a profile built for Valion Bio's current phase of growth. Lackey joins from Alaunos Therapeutics (TCRT), where she served as Senior Vice President of Legal & Administration.

Alaunos Therapeutics announced early data from two non-Good Laboratory Practice diet-induced obesity mouse studies evaluating ALN1003, the company's lead small-molecule drug candidate for treating obesity and related conditions, such as metabolic dysfunction-associated steatotic liver disease. ALN1003 is an oral small-molecule drug being developed for a non-hormonal, non-incretin approach, unlike hormone-based treatments like GLP-1 drugs. We conducted two separate studies using a standard diet-induced obesity mouse model in male C57BL/6 mice maintained on a high-fat diet. Highlights from these studies include dose-dependent body weight loss with favorable body composition changes, reductions in liver weight, decreases in liver injury enzymes and other liver-related biomarker, and improvement in metabolic biomarkers. Collectively, these findings suggest encouraging metabolic effects of ALN1003 in the DIO model.